Know Cancer

forgot password

A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults With Refractory Solid Tumors

Phase 1
2 Years
25 Years
Open (Enrolling)
Solid Tumors, Brain Tumors, Sarcoma, Wilm's Tumor, Rhabdomyosarcoma

Thank you

Trial Information

A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults With Refractory Solid Tumors


- Despite progress, some children and young adults with solid tumors still experience
poor survival.

- Activated NK cells potently kill autologous pediatric solid tumors, and clinical grade
procedures are available to generate large numbers of activated NK cells for adoptive
cell therapy.


- Primary objectives are: 1) to assess the feasibility of harvesting and expanding
activated NK cells to meet escalating dose goals in Cohort A, 2) to assess the toxicity
of infusing escalating doses of activated NK cells following lymphodepleting
chemotherapy without rhIL15 (cohort A), and 3) to assess the toxicity of infusing NK
activated cells with escalating doses of rhIL15 (cohort B) in pediatric patients with
refractory malignant solid tumors.

- Secondary objectives are: 1) to identify biologically active doses of activated
autologous NK cells plus or minus rhIL15 by monitoring changes in NK cell number,
phenotype and function, 2) to assess pharmacokinetics and immunogenicity of rhIL15 in a
pediatric population, and 3) assess antitumor effects and changes in FDG-PET following
administration of activated NK cells to lymphopenic hosts plus or minus rhIL15.


- Patients 2-25 years with refractory pediatric malignant solid tumors.

- Adequate performance status and organ function, recovered from toxic effects of prior
therapy, no requirement for systemic corticosteroids and no history of allogeneic stem
cell transplantation.


- All patients receive pre-NK lymphodepleting chemotherapy with cyclophosphamide.

- Cohort A receives escalating doses of activated autologous NK cells to identify
feasibility of generating cells and tolerability, and potentially identify an MTD.

- A1: 1x10(6) NK cells/kg

- A2: 1 x 10(7) NK cells/kg

- A3: 1 x 10(8) NK cells/kg

- If feasibility and acceptable toxicity is demonstrated for all doses in Cohort A,
patients enrolled on cohort B will receive activated autologous NK cells plus
escalating doses of rhIL15 using the following schema:

- B1: 1 x 10(7) NK cells/kg + rhIL15 0.25 mcg/kg/d IV x 12

- B2: 1 x 10(8) NK cells/kg + rhIL15 0.25 mcg/kg/d IV x 12

- B3: 1 x 10(8) NK cells/kg + rhIL15 0.5 mcg/kg/d IV x 12

- B4: 1 x 10(8) NK cells/kg + rhIL15 0.75 mcg/kg/d IV x 12

- Three patients will be enrolled at each dose level, with the dose level expanded to 6
if doselimiting toxicity occurs. An expanded group of 12 patients will be treated at
the highest tolerable dose level. DLT toxicity monitoring will continue for 21 days
after the NK infusion, or 14 days after the last rhIL15 dose in Cohort B (whichever is

Inclusion Criteria


- Diagnosis:

- Histologically confirmed solid tumors, including primary brain tumors. In subjects
with brain stem or optic gliomas the requirement for histological confirmation may be

- Age: 2 to less than or equal to 25 years old at the time of enrollment.

- Patients must have evaluable or measurable malignant disease at enrollment.

- Prior Therapy:

- The patient's malignancy must have relapsed after or failed to respond to frontline
curative therapy and/or there must not be any potentially curative treatment options
available at the time of study entry.

- There is no limit to the number of prior treatment regimens. However, patients must
have fully recovered from the acute toxic effects of all prior chemotherapy,
immunotherapy, or radiotherapy prior to study enrollment. Acute toxicity of any
previous therapy must have resolved to grade 1 or less, unless specified elsewhere.

- Myelosuppressive chemotherapy: Patients must not have received myelosuppressive
chemotherapy within 3 weeks of enrollment (6 weeks if prior nitrosourea).

- Hematopoietic growth factors: At least 7 days must have elapsed since the completion
of therapy with a growth factor. At least 14 days must have elapsed after receiving

- Biologic (anti-neoplastic agent) or metronomic non-myelosuppressive chemotherapy: At
least 7 days must have elapsed since the completion of therapy with a biologic agent.
For agents that have known adverse events occurring beyond 7 days after
administration, this period prior to enrollment must be extended beyond the time
during which adverse events are known to occur.

- Monoclonal antibodies: At least 4 weeks must have elapsed since prior therapy that
included a monoclonal antibody.

- Radiotherapy: 3 weeks must have elapsed since XRT

- Performance status: ECOG 0, 1 or 2, or for children less than or equal to10 years of
age, Lansky greater than or equal to 60. Note: Patients who are unable to walk
because of paralysis, but who are up in a wheelchair, will be considered ambulatory
for the purpose of assessing the performance score.

- Cardiac function: Left ventricular ejection fraction greater than or equal to 45% or
fractional shortening greater than or equal to28%.

- Liver function: Serum total bilirubin < 2 mg/dl, serum AST and ALT less than or
equal to 3 x upper limit of normal. Patients with Gilbert syndrome are excluded from
the requirement of a normal

bilirubin. (Gilbert syndrome is found in 3-10% of the general population, and is
characterized by mild, chronic unconjugated hyperbilirubinemia in the absence of liver
disease or overt hemolysis). On cohort B, patients with liver involvement by tumor will
not be eligible due to potential confounding risk for hepatotoxicity when rhIL15 is
administered. NOTE: adult values will be used for calculating hepatic toxicity on this
trial, as is standard on POB phase I trials.

- Renal function: Age-adjusted normal serum creatinine according to the following table or
a creatinine clearance greater than or equal to 60 ml/min/1.73 m(2).

Age (years) Maximum serum creatinine (mg/dl)

less than or equal to5 0.8

> 5 less than or equal to 10 1.0

> 10 less than or equal to 15 1.2

> 15 1.5

- Marrow function: ANC must be > 750/mm(3) (unless due to underlying disease in which
case there is no grade restriction), platelet count must be greater than or equal to
75,000/mm(3) (not achieved by transfusion). Lymphopenia, CD4 lymphopenia, leukopenia,
and anemia will not render patients ineligible.

- Female patients (and when relevant their male partners) must be willing to practice
birth control (including abstinence) during and for two months after treatment, if of
childbearing potential.

- Ability to give informed consent. For patients < 18 years of age their legal guardian
must give informed consent. Pediatric patients will be included in age-appropriate
discussion in order to obtain verbal assent.

- Durable power of attorney form completed (patients greater than or equal to18 years
of age only).


- Untreated CNS metastatic disease as defined by:

- Solid Tumors: History of untreated metastatic CNS tumor involvement. Extradural
masses which have not invaded the brain parenchyma or parameningeal tumors without
evidence for leptomeningeal spread will not render the patient ineligible. Patients
with previous CNS tumor involvement are eligible IF the CNS tumor(s) has been treated
and has been stable or resolving for at least 4 weeks; and if the patient does not
currently require steroids.

- Prior history allogeneic stem cell transplantation.

- Breast feeding or pregnant females (due to risk to fetus or newborn).

- HIV or HTLV-I/II (due to unacceptable risk associated with severe immune suppression
and risk associated with cell products).

- Hepatitis B surface antigen (HBsAg) positive or hepatitis C antibody positive with
elevated liver transaminases. All patients with chronic active hepatitis (including
those on antiviral therapy) are ineligible.

- Patients who require systemic corticosteroid or other systemic immunosuppressive
therapy. Immunosuppressive therapy must be stopped at least 28 days prior to
enrollment. Topical agents and/or inhaled corticosteroids are permitted.

- High risk of inability to comply with therapy in the estimation of the PI.

- Clinically significant systemic illness (e.g. serious active infections or
significant vital other organ dysfunction), that in the judgment of the PI would
likely compromise the patient's ability to tolerate protocol therapy or significantly
increase the risk of complications.


Both men and women of all races and ethnic groups are eligible for this trial.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Assess feasibility of harvesting + expanding activated NK cells in escalating doses in Cohort A;and assess toxicity of autologous activated and expanded NK cells following lymphodepleting chemotherapy + or - rhIL15 in pediatric patients w/ solid...

Outcome Time Frame:

3 years

Safety Issue:


Principal Investigator

Melinda S Merchant, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Cancer Institute (NCI)


United States: Federal Government

Study ID:




Start Date:

May 2013

Completion Date:

November 2022

Related Keywords:

  • Solid Tumors
  • Brain Tumors
  • Sarcoma
  • Wilm's Tumor
  • Rhabdomyosarcoma
  • NK Cells
  • Cytokine
  • Lymphodepleting Chemotherapy
  • Toxicity
  • Pharmacokinetics
  • Brain Neoplasms
  • Wilms Tumor
  • Rhabdomyosarcoma
  • Neoplasms
  • Sarcoma



National Institutes of Health Clinical Center, 9000 Rockville PikeBethesda, Maryland  20892